April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
A Clear, Mixed Nanomicellar Formulation of Voclosporin (LX214), Achieves Therapeutic Levels in Ocular Posterior Segment After Single and Multiple Topical Dosing in Rabbits
Author Affiliations & Notes
  • P. Velagaleti
    Lux Biosciences Inc, Jersey City, New Jersey
  • B. Gilger
    Department of Clinical Sciences, North Carolina State University, Raleigh, North Carolina
  • E. Anglade
    Lux Biosciences Inc, Jersey City, New Jersey
  • A. K. Mitra
    School of Pharmacy, University of Missouri, Kansas City, Missouri
  • Footnotes
    Commercial Relationships  P. Velagaleti, Lux Biosciences, Inc., E; B. Gilger, Lux Biosciences, Inc, C; E. Anglade, Lux Biosciences, Inc, E; A.K. Mitra, Lux Biosciences, Inc, F; Lux Biosciences, Inc, C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5323. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Velagaleti, B. Gilger, E. Anglade, A. K. Mitra; A Clear, Mixed Nanomicellar Formulation of Voclosporin (LX214), Achieves Therapeutic Levels in Ocular Posterior Segment After Single and Multiple Topical Dosing in Rabbits. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5323.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Voclosporin (VCS), a next-generation calcineurin inhibitor, may be an effective treatment for ocular posterior segment diseases. The potential for topical ocular delivery of [14C]LX214 (0.2% [14C]VCS nanomicellar ophthalmic solution) to the posterior segment of the eye was evaluated by examining the pharmacokinetics (PK) of radioactivity in ocular tissues, fluids, and blood in New Zealand White (NZW; albino) and Dutch Belted (DB; pigmented) rabbits after topical ocular application.

Methods: : NZW (30 female/8 male) and DB (16 female) rabbits received topical 0.2% [14C]LX214 in one or both eyes as a single (NZW and DB) or daily (NZW) dose for up to 7 days. [14C]LX214-derived radioactivity was measured in multiple ocular tissues/fluids and in whole blood. VCS was also measured in whole blood by LC-API/MS/MS (LOQ; 0.100 ng/mL). PK parameters (Cmax, Tmax) for [14C]LX214 were determined for blood, tear, and ocular tissues, and for parent drug in blood.

Results: : After a single dose of [14C]LX214, Cmax in the choroid/retina was 50 ng Eq/g (Tmax 1 hr) in both NZW and DB rabbits; Cmax in the optic nerve was 86 ng Eq/g (Tmax 0.5 hr) in NZW and 199 ng Eq/g (Tmax 1 hr) in DB rabbits, all well above the expected VCS therapeutic threshold of 30 ng Eq/g. After repeat dosing in NZW rabbits, choroid/retina and optic nerve VCS Cmax was 79 ng Eq/g (Tmax 2 hr) and 170 ng Eq/g (Tmax 0.5 hr), respectively. Blood concentrations of VCS were low in NZW and DB rabbits after a single dose (Cmax 1.73 and 1.28 ng/mL, respectively) at Tmax’s of 1 hr and after multiple dosing in NZW rabbits (Cmax was 1.16 ng/mL) at a Tmax of 0.5 hr. There were no gender differences in ocular tissue or whole blood VCS levels.

Conclusions: : Single and multiple topical applications of 0.2% [14C]LX214 resulted in therapeutic VCS concentrations in the choroid/retina and optic nerve in both albino (NZW) and pigmented (DB) rabbit eyes, providing evidence of the potential for use of a topical nanomicellar drug delivery platform in the treatment of ocular posterior segment diseases.

Keywords: development • retina • optic nerve 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.